Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit
Sana Biotechnology (NASDAQ: SANA) will present at the TD Cowen Immunology & Inflammation Summit on Wednesday, November 12, 2025 at 1:30 p.m. ET. The presentation, given by Steve Harr, President and CEO, will provide a business overview and company update.
The presentation will be webcast and available on Sana's Investor Relations website at https://sana.com/. A replay will be posted at the same location for 30 days after the conference.
Sana Biotechnology (NASDAQ: SANA) parteciperà al TD Cowen Immunology & Inflammation Summit mercoledì 12 novembre 2025 alle 13:30 ET. La presentazione, condotta da Steve Harr, presidente e amministratore delegato, offrirà una panoramica dell'attività e un aggiornamento sull'azienda.
La presentazione sarà trasmessa in webcast e disponibile sul sito delle Relazioni con gli Investitori di Sana all'indirizzo https://sana.com/. Una replica sarà pubblicata nello stesso sito per 30 giorni dopo la conferenza.
Sana Biotechnology (NASDAQ: SANA) participará en el TD Cowen Immunology & Inflammation Summit el miércoles, 12 de noviembre de 2025 a las 13:30 ET. La presentación, a cargo de Steve Harr, presidente y director general, proporcionará una visión general del negocio y una actualización de la empresa.
La presentación se transmitirá en vídeo en directo y está disponible en el sitio de Relaciones con Inversores de Sana en https://sana.com/. Una repetición estará publicada en el mismo sitio durante 30 días después de la conferencia.
Sana Biotechnology (NASDAQ: SANA)는 TD Cowen Immunology & Inflammation Summit에서 2025년 11월 12일 수요일 오후 1시 30분 ET에 발표할 예정입니다. 발표는 Steve Harr, 사장 겸 최고경영자가 진행하며, 비즈니스 개요와 회사 업데이트를 제공합니다.
발표는 웹캐스트로 생중계되며 Sana의 투자자 관계 웹사이트 https://sana.com/에서 확인할 수 있습니다. 재방송은 컨퍼런스 후 30일 동안 동일한 위치에 게시됩니다.
Sana Biotechnology (NASDAQ: SANA) participera au TD Cowen Immunology & Inflammation Summit le mercredi 12 novembre 2025 à 13 h 30 ET. La présentation, donnée par Steve Harr, président et directeur général, fournira un aperçu des activités et une mise à jour de l'entreprise.
La présentation sera diffusée en webcast et disponible sur le site des Relations investisseurs de Sana à l'adresse https://sana.com/. Une rediffusion sera publiée au même endroit pendant 30 jours après la conférence.
Sana Biotechnology (NASDAQ: SANA) wird am TD Cowen Immunology & Inflammation Summit am Mittwoch, dem 12. November 2025 um 13:30 ET präsentieren. Die Präsentation von Steve Harr, Vorsitzender und CEO, gibt einen Überblick über das Geschäft und ein Update zum Unternehmen.
Die Präsentation wird im Webcast übertragen und ist auf der Investor Relations-Website von Sana unter https://sana.com/ verfügbar. Eine Wiederholung wird am selben Ort für 30 Tage nach der Konferenz veröffentlicht.
Sana Biotechnology (NASDAQ: SANA) ستقدّم في TD Cowen Immunology & Inflammation Summit يوم الأربعاء 12 نوفمبر 2025 في تمام الساعة 1:30 ظهرًا بتوقيت شرق الولايات المتحدة. ستقدّم العرض ستيف هار، الرئيس والمدير التنفيذي، وسيقدّم نظرة عامة على الأعمال وتحديثًا عن الشركة.
سيتم بث العرض عبر الويب ومتاح على موقع علاقات المستثمرين لشانا على https://sana.com/. ستُنشَر إعادة تشغيله في نفس الموقع لمدة 30 يومًا بعد المؤتمر.
- None.
- None.
SEATTLE, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentation at the TD Cowen Immunology & Inflammation Summit at 1:30 p.m. ET on Wednesday, November 12, 2025. The presentation will feature a business overview and update by Steve Harr, Sana’s President and Chief Executive Officer.
The webcast will be accessible on the Investor Relations page of Sana’s website at https://sana.com/. A replay of the presentation will be available at the same location for 30 days following the conference.
About Sana Biotechnology
Sana Biotechnology, Inc. is focused on creating and delivering engineered cells as medicines for patients. We share a vision of repairing and controlling genes, replacing missing or damaged cells, and making our therapies broadly available to patients. We are a passionate group of people working together to create an enduring company that changes how the world treats disease. Sana has operations in Seattle, WA, Cambridge, MA, and South San Francisco, CA. For more information about Sana Biotechnology, please visit https://sana.com/.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Sana Biotechnology, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including those related to the Company’s vision; the Company’s participation at the TD Cowen Immunology & Inflammation Summit; and the subject matter of the Company’s presentation at the conference. All statements other than statements of historical facts contained in this press release, including, among others, statements regarding the Company’s strategy, expectations, future operations, and prospects, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “design,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “positioned,” “potential,” “predict,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs. In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. These statements are subject to risks and uncertainties that could cause the actual results to vary materially, including, among others, the risks inherent in drug development such as those associated with the initiation, cost, timing, progress and results of the Company’s current and future research and development programs, preclinical and clinical trials, as well as economic, market and social disruptions. For a detailed discussion of the risk factors that could affect the Company’s actual results, please refer to the risk factors identified in the Company’s SEC reports, including but not limited to its Quarterly Report on Form 10-Q dated August 11, 2025. Except as required by law, the Company undertakes no obligation to update publicly any forward-looking statements for any reason.
Investor Relations & Media:
Nicole Keith
investor.relations@sana.com
media@sana.com
FAQ
When is Sana Biotechnology (SANA) presenting at the TD Cowen Immunology & Inflammation Summit?
Who will present for Sana (SANA) at the November 12, 2025 summit?
Where can investors watch the Sana (SANA) webcast for the TD Cowen summit?
How long will the Sana (SANA) summit presentation replay remain online?
What will Sana (SANA) cover in its November 12, 2025 presentation?
